The lymphocyte subpopulation in patients with duodenal ulcer and the immunocorrective activity of thymalin and dalargin
Lukash NV, Polishchuk TF, Ludan VV · 1998 · Lik Sprava. 1998;(3):56-58. PMID 9695565
This source appears in the Thymalin–Dalargin evidence review. A single-agent experiment, comparative study or patent alternative is not automatically a combined-treatment trial.
Reported findings and study design
Narrative findings; numerical extraction incomplete
The abstract reports movement of reduced T-cell rosette indices toward healthy-reference values during peptide-containing care. It does not establish which patients received each peptide or whether the pair was given together.
120 patients with uncomplicated duodenal ulcer; 30 healthy donors used as immune-reference controls. Treatment-arm sizes and allocation are unavailable.
Protocol information
Dose, route and treatment schedule are not sufficiently described in the checked abstract.
Protocol source ↗ · Original indexed abstract; protocol unavailable
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| T-cell immune measurements | Improvement toward healthy-reference levels reported; no numerical treatment effect or arm-specific denominator supplied | E-rosette and theophylline-sensitive/resistant assays; healthy donors are reference controls, not an untreated ulcer-treatment arm |
| Unchanged index and source inconsistency | The abstract says TFS-RFC did not differ from controls before or after treatment | The same abstract uses inconsistent TPP/TPS/TFP/TFS abbreviations and also lists reduced indices; exact subset interpretation requires the original paper |
| Clinical cohort | 120 ulcer patients and 30 healthy donors | These totals do not establish randomization, treatment-group sizes or simultaneous dual treatment |
| Clinical healing and safety | No ulcer-closure rate, relapse rate, adverse-event count or combination-specific clinical endpoint in the checked abstract | |
| Dose, route and schedule | Not supplied in the checked abstract |
This is the direct human research lead, with unresolved exposure assignment. It is not a verified combination trial or a validated healing regimen. The neutral sentence and inconsistent abbreviations remain visible.
Source for the extracted data ↗ · Checked 2026-11-08
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Original treatment-arm table, doses, routes, concurrent care, allocation and follow-up not recovered.
- Historical rosette subpopulations must not be relabeled as modern flow-cytometry CD4/CD8 or regulatory T-cell measurements.
- Healthy donor references do not control for other ulcer treatments. The abstract does not prove simultaneous coadministration, additive benefit or synergy.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original indexed abstract
Review depth: Indexed abstract and citation checked; full original outcome tables not recovered
Related-report group: lukash-polishchuk-ulcer-1998. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Original journal publication
Citation and original source
Original source: Lukash NV, Polishchuk TF, Ludan VV. The lymphocyte subpopulation in patients with duodenal ulcer and the immunocorrective activity of thymalin and dalargin Lik Sprava. 1998;(3):56-58. PMID 9695565 1998.
Molekul research summary: https://molekul.io/research/thymalin-dalargin-ulcer-1998. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Thymalin
Thymus-derived peptide mixture with historical Russian studies in autoimmune cytopenias and thyroiditis, alongside other treatments. It is distinct from synthetic Thymogen and Thymodepressin.
Dalargin
A Soviet synthetic opioid hexapeptide investigated in cytoprotection, stress, hypoxia, ischemia and trauma. Its enkephalin lineage is distinct from organ-derived peptide bioregulators; historical proposals and laboratory effects are not established clinical indications.